Concepedia

Publication | Open Access

Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

DOIFull Paper Access

169

Citations

17

References

2021

Year

Nancy M. Holekamp, Peter A. Campochiaro, Margaret Chang, Daniel M. Miller, Dante J. Pieramici, Anthony P. Adamis, Christopher Brittain, Erica Evans, Derrick Kaufman, Katie F. Maass,
Ophthalmology

Abstract

Archway met its primary objective and PDS Q24W demonstrated noninferior and equivalent efficacy to monthly ranibizumab, with 98.4% of PDS-treated patients not receiving supplemental treatment in the first 24-week interval.

References

YearCitations

Page 1